Allianz Life goes go on Accenture Life Insurance Platform Accenture announced today that Allianz LIFE INSURANCE COVERAGE Company of North America has truly gone live on the Accenture Life Insurance Platform, its annuity and life insurance coverage software suite. The new system supports Allianz Life's new business and core policy administration needs for its variable annuity products. The operational system embeds industry guidelines and helps us stay in front of the market. Working closely with the Allianz Lifestyle team, Accenture replaced a core system with the brand new software within an agreed-upon timeline for over 100 users involved with new business and plan administration. The Accenture Life Insurance Platform provides Allianz Lifestyle with a far more modern, flexible operating platform that positions us to meet up our future product consumer and development service requirements, said Jasmine Jirele, senior vice president enterprise procedures at Allianz Life.Food and Drug Administration provides granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate , an enzyme co-factor alternative therapy for the treatment of patients with molybdenum cofactor insufficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic harm within the initial weeks of life. According to the FDA, a Breakthrough Therapy designation is made to expedite the development of a medication to treat a significant or life-threatening disease when preliminary scientific proof indicates that the medication may demonstrate considerable improvement over existing therapies using one or even more clinically significant endpoints.